U.S. Food and Drug Administration (FDA) Approves Recombinant Protein Treatment for Tibia Fractures
Wyeth's rhBMP-2/ACS Offers Potential for Improved Fracture Healing
04-May-2004 -
Madison, N.J. Wyeth announced that the FDA has approved rhBMP-2/ACS (recombinant human
Bone Morphogenetic Protein-2/Absorbable Collagen Sponge), a novel
protein device that enhances bone healing, for use in the treatment of
acute, open tibia shaft fractures in adults. The device consists ...
food
genetics
milestone payments
+4